Compare EOCN & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EOCN | SXTP |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.6M |
| IPO Year | 2013 | 2023 |
| Metric | EOCN | SXTP |
|---|---|---|
| Price | $3.22 | $0.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.70 |
| AVG Volume (30 Days) | 5.6K | ★ 135.7K |
| Earning Date | 11-25-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,005,471.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.49 |
| 52 Week Low | $3.12 | $0.34 |
| 52 Week High | $3.80 | $8.62 |
| Indicator | EOCN | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 37.97 |
| Support Level | $3.12 | $0.84 |
| Resistance Level | $3.80 | $1.66 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 26.47 | 0.14 |
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.